Eupraxia Pharmaceuticals held successful shareholder meeting and is developing multiple medical products

From GlobeNewswire: 2025-06-02 18:30:00

Eupraxia Pharmaceuticals Inc. held its Annual General and Special Meeting of Shareholders on June 2, 2025. All six nominees for the board of directors were elected by ballot vote. Other business items, including re-appointing KPMG LLP as the auditor, were also passed by shareholders. The company focuses on developing locally delivered, extended-release products using its proprietary DiffuSphere™ technology to target areas with high unmet medical needs. Eupraxia’s EP-104GI is in a Phase 1b/2a trial for EoE treatment, and their EP-104IAR recently completed a successful Phase 2b trial for knee osteoarthritis pain. The company is also developing a pipeline for other inflammatory joint indications and oncology.



Read more at GlobeNewswire: Eupraxia Pharmaceuticals Announces Voting Results from